Clinical Trial Update: Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating self-administered injections of BMN165 for adults with phenylketonuria has completed; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• BMN165

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Phenylketonuria (PKU) | Phase 3 | Status: COMPLETED | Results posted: 2019-07-12